SLXN Silexion Therapeutics Corp.

NASDAQ
$1.65

Silexion Therapeutics Corp. (SLXN) is expected to report earnings on February 11, 2027, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of -35.3% since its last earnings release on November 12, 2026.

Silexion Therapeutics Reported Earnings
Friday, November 13, 2026 · 9:03 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 8:45 AM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.90

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Silexion Therapeutics Corp.

Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. Silexion Therapeutics Ltd., formerly known as Biomotion Sciences, is based in NEW YORK.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.